Corrigendum to “Retrospective analysis of the efficacy and safety of 100 mg abrocitinib in patients with moderate to severe atopic dermatitis: Real-world study” [World Allergy Organ J 16 (2) (2023) 101167]

Maoying Li; Cuihong Lian; Xi Wang

doi:10.1016/j.waojou.2026.101378

April 17, 2026World Allergy Organization JournalOpen Access

Corrigendum to “Retrospective analysis of the efficacy and safety of 100 mg abrocitinib in patients with moderate to severe atopic dermatitis: Real-world study” [World Allergy Organ J 16 (2) (2023) 101167]

View Full Paper

Ask AI

Bookmark

Share

Key Points

To correct data representation errors in a previous real-world study on abrocitinib for atopic dermatitis.
Correction of data presentation in two comparison groups.
Review of original medical records for accurate data.
Reconfirmation of P-values and statistical interpretations.
Duplicate data between comparison groups was identified and corrected.
The patient distribution in medication background categories was accurately represented in the corrected table.
Overall conclusions and statistical interpretations remain unchanged.

Ask about this paper

Answers are grounded in this paper and cite their sources.

Implication

This corrigendum addresses data presentation errors affecting the efficacy and safety evaluation of abrocitinib in atopic dermatitis, indicating the need for accurate data reporting.

Abstract

No abstract yet. The journal hasn't published one we can show.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Li et al. (2026) studied this question.

synapsesocial.com/papers/69e5c2d003c2939914028ce9 https://doi.org/10.1016/j.waojou.2026.101378

View Full Paper

Ask AI

Bookmark

Share

Corrigendum to “Retrospective analysis of the efficacy and safety of 100 mg abrocitinib in patients with moderate to severe atopic dermatitis: Real-world study” [World Allergy Organ J 16 (2) (2023) 101167]

Key Points

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Corrigendum to “Retrospective analysis of the efficacy and safety of 100 mg abrocitinib in patients with moderate to severe atopic dermatitis: Real-world study” [World Allergy Organ J 16 (2) (2023) 101167]

Key Points

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading